InsiderClue
Stocks · Health care · Pharmaceutical Preparations

ASCENTAGE PHARMA GROUP INTERNATIONAL

AAPG Clue Score55
Cayman Islands Fiscal year ends December CIK 0002023311
$14.75 +1.37% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $14.75 −60.15% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 24 Jan 2025. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueNet income
Fiscal year 2022Revenue209.7Net income−882.9EPS, diluted−3.35Fiscal year 2023Revenue222.0 +5.9%Net income−925.6EPS, diluted−3.28Fiscal year 2024Revenue980.7 +341.8%Net income−405.4EPS, diluted−1.34
FY2022FY2023FY2024
Revenue 209.7 222.0 980.7
Growth +5.9% +341.8%
Net income −882.9 −925.6 −405.4
Growth
EPS, diluted −3.35 −3.28 −1.34
Growth

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Gross marginNet margin
Fiscal year 2022Gross margin89.5%Net margin−421.0%Free cash flow margin−408.8%Fiscal year 2023Gross margin86.2%Net margin−417.0%Free cash flow margin−347.9%Fiscal year 2024Gross margin97.0%Net margin−41.3%Free cash flow margin−13.8%
FY2022FY2023FY2024
Gross margin 89.5% 86.2% 97.0%
Net margin −421.0% −417.0% −41.3%
Free cash flow margin −408.8% −347.9% −13.8%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2022Operating cash flow−653.9Capital expenditure−203.3Free cash flow−857.2Buybacks−26.8Fiscal year 2023Operating cash flow−726.1Capital expenditure−46.1Free cash flow−772.2Buybacks−5.9Fiscal year 2024Operating cash flow−111.4Capital expenditure−24.3Free cash flow−135.6
FY2022FY2023FY2024
Operating cash flow −653.9 −726.1 −111.4
Capital expenditure −203.3 −46.1 −24.3
Free cash flow −857.2 −772.2 −135.6
Growth
Buybacks −26.8 −5.9 n/a

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2022Cash1,345.6Shareholders’ equity408.7Fiscal year 2023Cash1,038.0Total debt1,198.4Net cash (debt)−160.3Shareholders’ equity60.4Debt to equity19.83Fiscal year 2024Cash893.1Total debt918.8Net cash (debt)−25.7Shareholders’ equity264.2Debt to equity3.48
FY2022FY2023FY2024
Cash 1,345.6 1,038.0 893.1
Total debt n/a 1,198.4 918.8
Net cash (debt) n/a −160.3 −25.7
Shareholders’ equity 408.7 60.4 264.2
Debt to equity n/a 19.83 3.48

In millions of CNY, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2024 · 10-K

Cash flow

In millions of CNY, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024
Operations
−653.9 −726.1 −111.4
Growth
Investment
−203.3 −46.1 −24.3
calc −857.2 −772.2 −135.6
Growth
−384.6 21.9 −362.0
Financing
619.3 368.8 314.8
−26.8 −5.9 n/a

Lines marked calc are worked out here from filed figures; point at one for how. Capital expenditure, dividends and buybacks are shown as money out, so negative. Shown in CNY as filed; the screener converts to dollars.